Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY

We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Teva Pharmaceutical Industries Limited is one of them.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) tops our list for being one of the overlooked stocks. It is experiencing strong momentum driven by recent product innovations and strategic initiatives. A major development is the FDA approval of AJOVY for pediatric migraine patients aged 6–17, expanding TEVA’s reach in the pediatric market. The company also reported its 10th consecutive quarter of growth, fueled by key products such as AUSTEDO, AJOVY, and UZEDY, which have seen significant sales increases in 2025.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s “Pivot to Growth” strategy focuses on innovation, operational efficiency, and specialty pharmaceutical expansion. The company targets a 30% operating margin by 2027 and plans to achieve approximately $700 million in net cost savings, building on $140 million in annual run-rate savings already realized in 2025. This transformation supports both its generics foundation and the growth of specialty medicines.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is actively advancing its R&D pipeline, including duvakitug, a Phase 3 candidate for autoimmune diseases like ulcerative colitis and Crohn’s disease. This focus on innovative specialty therapies, alongside strong generics and biosimilars performance, positions Teva for long-term growth.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.